Telomerase reverse transcriptase promoter mutations in hepatitis B virus-associated hepatocellular carcinoma

Oncotarget

Volumn 7, Issue 19, 2016, Pages 27838-27847

  Yang, Xunjun ^a,b   Guo, Xiuchan ^a,c   Chen, Yao ^d   Chen, Guorong ^d   Ma, Yin ^a   Huang, Kate ^d   Zhang, Yuning ^a   Zhao, Qiongya ^a   Winkler, Cheryl A ^e   An, Ping ^e   Lyu, Jianxin ^a  

^a WENZHOU MEDICAL UNIVERSITY   (China)

^b THE SECOND AFFILIATED HOSPITAL AND YUYING CHILDREN S HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^c ICF INTERNATIONAL   (United States)

^d THE FIRST AFFILIATED HOSPITAL OF WENZHOU MEDICAL UNIVERSITY   (China)

^e FREDERICK NATIONAL LABORATORY FOR CANCER RESEARCH   (United States)

Author keywords

Hepatocellular carcinoma; Mutation; Telomerase reverse transcriptase; TERT

Indexed keywords

ALPHA FETOPROTEIN; TELOMERASE REVERSE TRANSCRIPTASE; TELOMERASE; TERT PROTEIN, HUMAN; TUMOR MARKER;

ADULT; AGE; ARTICLE; CHINESE; CONTROLLED STUDY; DIFFERENTIAL DIAGNOSIS; DISEASE ASSOCIATION; DNA SEQUENCE; FAMILY HISTORY; FEMALE; GENE FREQUENCY; GENE MUTATION; GENE SEQUENCE; HEPATITIS B; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LIVER CELL CARCINOMA; MAJOR CLINICAL STUDY; MALE; MUTATIONAL ANALYSIS; PROMOTER REGION; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; SOMATIC MUTATION; TELOMERASE REVERSE TRANSCRIPTASE GENE; AGED; ASIAN CONTINENTAL ANCESTRY GROUP; BIOPSY; BLOOD; GENETICS; HEPATITIS B VIRUS; ISOLATION AND PURIFICATION; LIVER TUMOR; METABOLISM; MIDDLE AGED; MUTATION; PATHOLOGY; VERY ELDERLY; VIROLOGY; YOUNG ADULT;

ADULT; AGED; AGED, 80 AND OVER; ALPHA-FETOPROTEINS; ASIAN CONTINENTAL ANCESTRY GROUP; BIOMARKERS, TUMOR; BIOPSY; CARCINOMA, HEPATOCELLULAR; FEMALE; HEPATITIS B; HEPATITIS B VIRUS; HUMANS; LIVER NEOPLASMS; MALE; MIDDLE AGED; MUTATION; PROMOTER REGIONS, GENETIC; SEQUENCE ANALYSIS, DNA; TELOMERASE; YOUNG ADULT;

EID: 84968813860     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.8539     Document Type: Article

References (42)

1. El-Serag HB, Rudolph KL. Hepatocellular carcinoma: epidemiology and molecular carcinogenesis. Gastroenterology. 2007; 132:2557-2576.
2. Chen W, Zheng R, Baade PD, Zhang S, Zeng H, Bray F, Jemal A, Yu XQ, He J. Cancer statistics in China, 2015. CA Cancer J Clin. 2016; 66:115-132.
3. Singal AG, Pillai A, Tiro J. Early detection, curative treatment, and survival rates for hepatocellular carcinoma surveillance in patients with cirrhosis: a meta-analysis. PLoS Med. 2014; 11:e1001624.
4. Forner A, Llovet JM, Bruix J. Hepatocellular carcinoma. Lancet. 2012; 379:1245-1255.
5. Zhu Q, Li N, Zeng X, Han Q, Li F, Yang C, Lv Y, Zhou Z, Liu Z. Hepatocellular carcinoma in a large medical center of China over a 10-year period: evolving therapeutic option and improving survival. Oncotarget. 2015; 6:4440-4450. doi: 10.18632/oncotarget.2913.
6. Arzumanyan A, Reis HM, Feitelson MA. Pathogenic mechanisms in HBV-and HCV-associated hepatocellular carcinoma. Nat Rev Cancer. 2013; 13:123-135.
7. Mitchell M, Gillis A, Futahashi M, Fujiwara H, Skordalakes E. Structural basis for telomerase catalytic subunit TERT binding to RNA template and telomeric DNA. Nature structural & molecular biology. 2010; 17:513-518.
8. Pinyol R, Tovar V, Llovet JM. TERT promoter mutations: Gatekeeper and driver of hepatocellular carcinoma. J Hepatol. 2014; 61:685-687.
9. Kim NW, Piatyszek MA, Prowse KR, Harley CB, West MD, Ho PdL, Coviello GM, Wright WE, Weinrich SL, Shay JW. Specific association of human telomerase activity with immortal cells and cancer. Science. 1994; 266:2011-2015.
10. Kong F, Zheng C, Xu D. Telomerase as a "stemness" enzyme. Science China Life Sciences. 2014; 57:564-570.
11. Killela PJ, Reitman ZJ, Jiao Y, Bettegowda C, Agrawal N, Diaz LA, Jr., Friedman AH, Friedman H, Gallia GL, Giovanella BC, Grollman AP, He TC, He Y, Hruban RH, Jallo GI, Mandahl N, et al. TERT promoter mutations occur frequently in gliomas and a subset of tumors derived from cells with low rates of self-renewal. Proc Natl Acad Sci U S A. 2013; 110:6021-6026.
12. Huang FW, Hodis E, Xu MJ, Kryukov GV, Chin L, Garraway LA. Highly recurrent TERT promoter mutations in human melanoma. Science. 2013; 339:957-959.
13. Horn S, Figure lA, Rachakonda PS, Fischer C, Sucker A, Gast A, Kadel S, Moll I, Nagore E, Hemminki K, Schadendorf D, Kumar R. TERT promoter mutations in familial and sporadic melanoma. Science. 2013; 339:959-961.
14. Li C, Wu S, Wang H, Bi X, Yang Z, Du Y, He L, Cai Z, Wang J, Fan Z. The C228T mutation of TERT promoter frequently occurs in bladder cancer stem cells and contributes to tumorigenesis of bladder cancer. Oncotarget. 2015; 6:19542-19551. doi: 10.18632/oncotarget.4295.
15. Wang K, Liu T, Liu L, Liu J, Liu C, Wang C, Ge N, Ren H, Yan K, Hu S, Bjorkholm M, Fan Y, Xu D. TERT promoter mutations in renal cell carcinomas and upper tract urothelial carcinomas. Oncotarget. 2014; 5:1829-1836. doi: 10.18632/oncotarget.1829.
16. Xing M, Liu R, Liu X, Murugan AK, Zhu G, Zeiger MA, Pai S, Bishop J. BRAF V600E and TERT promoter mutations cooperatively identify the most aggressive papillary thyroid cancer with highest recurrence. J Clin Oncol. 2014; 32:2718-2726.
17. Wang N, Liu T, Sofiadis A, Juhlin CC, Zedenius J, Hoog A, Larsson C, Xu D. TERT promoter mutation as an early genetic event activating telomerase in follicular thyroid adenoma (FTA) and atypical FTA. Cancer. 2014; 120:2965-2979.
18. Liu X, Qu S, Liu R, Sheng C, Shi X, Zhu G, Murugan AK, Guan H, Yu H, Wang Y, Sun H, Shan Z, Teng W, Xing M. TERT Promoter Mutations and Their Association with BRAF V600E Mutation and Aggressive Clinicopathological Characteristics of Thyroid Cancer. J Clin Endocrinol Metab. 2014; 99:E1130-1136.
19. Heidenreich B, Rachakonda PS, Hemminki K, Kumar R. TERT promoter mutations in cancer development. Curr Opin Genet Dev. 2014; 24:30-37.
20. Nault JC, Mallet M, Pilati C, Calderaro J, Bioulac-Sage P, Laurent C, Laurent A, Cherqui D, Balabaud C, Zucman-Rossi J. High frequency of telomerase reverse-transcriptase promoter somatic mutations in hepatocellular carcinoma and preneoplastic lesions. Nat Commun. 2013; 4:2218.
21. Nault JC, Calderaro J, Di Tommaso L, Balabaud C, Zafrani ES, Bioulac-Sage P, Roncalli M, Zucman-Rossi J. Telomerase reverse transcriptase promoter mutation is an early somatic genetic alteration in the transformation of premalignant nodules in hepatocellular carcinoma on cirrhosis. Hepatology. 2014; 60:1983-1992.
22. Chen YL, Jeng YM, Chang CN, Lee HJ, Hsu HC, Lai PL, Yuan RH. TERT promoter mutation in resectable hepatocellular carcinomas: a strong association with hepatitis C infection and absence of hepatitis B infection. Int J Surg. 2014; 12:659-665.
23. Quaas A, Oldopp T, Tharun L, Klingenfeld C, Krech T, Sauter G, Grob TJ. Frequency of TERT promoter mutations in primary tumors of the liver. Virchows Archiv. 2014; 465:673-677.
24. Cevik D, Yildiz G, Ozturk M. Common telomerase reverse transcriptase promoter mutations in hepatocellular carcinomas from different geographical locations. World J Gastroenterol. 2015; 21:311-317.
25. Kawai-Kitahata F, Asahina Y, Tanaka S, Kakinuma S, Murakawa M, Nitta S, Watanabe T, Otani S, Taniguchi M, Goto F, Nagata H, Kaneko S, Tasaka-Fujita M, Nishimura-Sakurai Y, Azuma S, Itsui Y, et al. Comprehensive analyses of mutations and hepatitis B virus integration in hepatocellular carcinoma with clinicopathological features. J Gastroenterol. 2015. PMID:26553052. [Epub ahead of print].
26. Sturgeon CM, Duffy MJ, Hofmann BR, Lamerz R, Fritsche HA, Gaarenstroom K, Bonfrer J, Ecke TH, Grossman HB, Hayes P, Hoffmann RT, Lerner SP, Lohe F, Louhimo J, Sawczuk I, Taketa K, et al. National Academy of Clinical Biochemistry Laboratory Medicine Practice Guidelines for use of tumor markers in liver, bladder, cervical, and gastric cancers. Clin Chem. 2010; 56:e1-48.
27. Qin S, Primary Liver Cancer D and Treatment Expert Panel of the Chinese Ministry of H. Guidelines on the diagnosis and treatment of primary liver cancer (2011 edition). Chin Clin Oncol. 2012; 1:10.
28. Peng SY, Chen WJ, Lai PL, Jeng YM, Sheu JC, Hsu HC. High alpha-fetoprotein level correlates with high stage, early recurrence and poor prognosis of hepatocellular carcinoma: significance of hepatitis virus infection, age, p53 and beta-catenin mutations. Int J Cancer. 2004; 112:44-50.
29. Yao M, Zhao J, Lu F. Alpha-fetoprotein still is a valuable diagnostic and prognosis predicting biomarker in hepatitis B virus infection-related hepatocellular carcinoma. Oncotarget. 2016; 7: 3702-3708. doi: 10.18632/oncotarget.6913.
30. Vinagre J, Pinto V, Celestino R, Reis M, Populo H, Boaventura P, Melo M, Catarino T, Lima J, Lopes JM, Maximo V, Sobrinho-Simoes M, Soares P. Telomerase promoter mutations in cancer: an emerging molecular biomarker? Virchows Arch. 2014; 465:119-133.
31. Sung WK, Zheng H, Li S, Chen R, Liu X, Li Y, Lee NP, Lee WH, Ariyaratne PN, Tennakoon C, Mulawadi FH, Wong KF, Liu AM, Poon RT, Fan ST, Chan KL, et al. Genome-wide survey of recurrent HBV integration in hepatocellular carcinoma. Nat Genet. 2012; 44:765-769.
32. Chen Y, Kong Q. Nuclear translocation of telomerase reverse transcriptase: a critical process in chemical induced hepatocellular carcinogenesis. Neoplasma. 2010; 57:222-227.
33. Zavlaris M, Angelopoulou K, Vlemmas I, Papaioannou N. Telomerase reverse transcriptase (TERT) expression in canine mammary tissues: a specific marker for malignancy? Anticancer Res. 2009; 29:319-325.
34. Huang HN, Chiang YC, Cheng WF, Chen CA, Lin MC, Kuo KT. Molecular alterations in endometrial and ovarian clear cell carcinomas: clinical impacts of telomerase reverse transcriptase promoter mutation. Mod Pathol. 2015; 28:303-311.
35. Vinagre J, Almeida A, Pópulo H, Batista R, Lyra J, Pinto V, Coelho R, Celestino R, Prazeres H, Lima L. Frequency of TERT promoter mutations in human cancers. Nature communications. 2013; 4.
36. Liu T, Wang N, Cao J, Sofiadis A, Dinets A, Zedenius J, Larsson C, Xu D. The age-and shorter telomere-dependent TERT promoter mutation in follicular thyroid cell-derived carcinomas. Oncogene. 2014; 33:4978-4984.
37. Simon M, Hosen I, Gousias K, Rachakonda S, Heidenreich B, Gessi M, Schramm J, Hemminki K, Waha A, Kumar R. TERT promoter mutations: a novel independent prognostic factor in primary glioblastomas. Neuro Oncol. 2015; 17:45-52.
38. Jin C, Chen J, Meng Q, Carreira V, Tam NN, Geh E, Karyala S, Ho SM, Zhou X, Medvedovic M, Xia Y. Deciphering gene expression program of MAP3K1 in mouse eyelid morphogenesis. Dev Biol. 2013; 374:96-107.
39. Kleihues P, Sobin LH. World Health Organization classification of tumors. Cancer. 2000; 88:2887-2887.
40. Sobin LH, Fleming ID. TNM classification of malignant tumors, fifth edition (1997). Cancer. 1997; 80:1803-1804.
41. Pikor LA, Enfield KS, Cameron H, Lam WL. DNA extraction from paraffin embedded material for genetic and epigenetic analyses. J Vis Exp. 2011;:e2763.
42. Brustmann H. Immunohistochemical detection of human telomerase reverse transcriptase (hTERT) and c-kit in serous ovarian carcinoma: a clinicopathologic study. Gynecologic oncology. 2005; 98:396-402.